TY - JOUR
T1 - Efficacy and toxicity of bevacizumab in recurrent ovarian disease: An update meta-analysis on phase III trials
AU - Marchetti, Claudia
AU - De Felice, Francesca
AU - Palaia, Innocenza
AU - Musella, Angela
AU - Di Donato, Violante
AU - Gasparri, Maria Luisa
AU - Musio, Daniela
AU - Muzii, Ludovico
AU - Tombolini, Vincenzo
AU - Panici, Pierluigi Benedetti
PY - 2016
Y1 - 2016
N2 - Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.
AB - Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.
KW - Bevacizumab
KW - Ovarian cancer
KW - Recurrent
KW - Survival
KW - Toxicity
KW - Bevacizumab
KW - Ovarian cancer
KW - Recurrent
KW - Survival
KW - Toxicity
UR - http://hdl.handle.net/10807/201326
U2 - 10.18632/oncotarget.6507
DO - 10.18632/oncotarget.6507
M3 - Article
SN - 1949-2553
VL - 7
SP - 13221
EP - 13227
JO - Oncotarget
JF - Oncotarget
ER -